GWS
REGN icon

Greykasell Wealth Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History

Greykasell Wealth Strategies’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298K Hold
478
– – 0.11% 120
2026
Q1 		$369K Hold
478
– – 0.15% 106
2025
Q4 		$369K Buy
478
+113
+31% +$76.7K 0.15% 107
2025
Q3 		$205K Sell
365
-34
-9% -$19.2K 0.09% 136
2025
Q2 		$209K Sell
399
-309
-44% -$172K 0.1% 129
2025
Q1 		$449K Hold
708
– – 0.24% 86
2024
Q4 		$504K Buy
+708
New +$594K 0.28% 84

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Greykasell Wealth Strategies's REGN Position: Q2 2026 in Review

Greykasell Wealth Strategies held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 478 shares worth $298K. The position accounts for 0.11% of the portfolio, ranked #120.

Greykasell Wealth Strategies first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $504K in Q4 2024. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Greykasell Wealth Strategies held 478 shares of Regeneron Pharmaceuticals worth $298K as of Q2 2026.
  • Greykasell Wealth Strategies left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up 0.11% of Greykasell Wealth Strategies's portfolio in Q2 2026, its #120 holding.
  • Greykasell Wealth Strategies first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Greykasell Wealth Strategies's Regeneron Pharmaceuticals position peaked at $504K in Q4 2024.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Greykasell Wealth Strategies's 13F filing for Q2 2026, filed 11 Aug 2026.